2026-525700-10-00招募中1 期
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ST‑905‑AG1 in Healthy Volunteers
Syremis Therapeutics Ltd.1 个研究点 分布在 1 个国家目标入组 280 人开始时间: 2026年4月20日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 280
- 试验地点
- 1
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 64 years（18-64 Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
Head of Clinical Pharmacology
Scientific
Syremis Therapeutics Ltd.
研究点 (1)
Loading locations...
相似试验
招募中
1 期
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Clinical Activity of BBT002 in Healthy Volunteers and Patients with Chronic Obstructive Pulmonary Disease (COPD) or Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) and Comorbid Asthma2025-523142-28-00Bambusa Therapeutics Inc.36
招募中
1 期
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL628 in Participants with Early Alzheimer’s Disease2025-523515-11-00Denali Therapeutics Inc.27
已完成
1 期
A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7486967 in Participants with Early Idiopathic Parkinson’s Disease2023-504412-14-00F. Hoffmann-La Roche AG, F. Hoffmann-La Roche AG20
暂停
1 期
A study to investigate the safety, tolerability, pharmacokinetics, immunogenicity and pharmacodynamics of a single subcutaneous dose of GSK4771261 in healthy participants aged 25 to 55 years of age inclusiveAutosomal Dominant Polycystic Kidney Disease2025-525073-37-00Glaxosmithkline Research & Development Limited30
已完成
1 期
A study to investigate the safety, tolerability, pharmacokinetics, and early signs of biological activity of danegaptide following oral administration in participants with diabetic macular edema2023-503683-16-00Breye Therapeutics ApS3